CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

    NEXT STORY
    Celebrating the Promise of a New Year
    PREV STORY
    Psyence Group Inc Completes Reverse Takeover Transaction and Completes Non-brokered Financing
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Aquinox Pharmaceuticals Announces Year End 2015 Financial Results

    VANCOUVER, British Columbia, March 08, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), ...

    author_avatar
    NASDAQ Market News

    Synthorx to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    author_avatar
    NASDAQ Market News

    Iterum Therapeutics Reports Second Quarter 2019 Financial Results

    author_avatar
    NASDAQ Market News